AbbVie's (ABBV) Outperform Rating Reiterated at Royal Bank Of Canada

Key Points

• Royal Bank of Canada reaffirmed its Outperform rating on AbbVie and maintained a $280 price target, implying only about 1% upside from the stock’s previous close. The analyst consensus remains “Moderate Buy,” with an average target of $277.18.
• AbbVie beat quarterly expectations with $3.65 in EPS and $16.99 billion in revenue, while revenue increased 10.2% year over year. Analysts expect the company to report $13.94 in EPS for the current fiscal year.
• Key risks include Humira’s ongoing decline, competition in immunology and AbbVie’s elevated valuation; meanwhile, institutional investors own 70.23% of the stock and an executive recently sold shares worth approximately $8.18 million.

AbbVie (NYSE:ABBV - Get Free Report)'s stock had its "outperform" rating reissued by analysts at Royal Bank Of Canada in a research note issued on Tuesday, Benzinga reports. They presently have a $280.00 target price on the stock. Royal Bank Of Canada's price target suggests a potential upside of 1.05% from the stock's previous close.

A number of other equities analysts also recently commented on ABBV. Leerink Partners upped their target price on shares of AbbVie from $245.00 to $279.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 5th. Wolfe Research raised shares of AbbVie from a "peer perform" rating to an "outperform" rating and lifted their price target for the company from $235.00 to $300.00 in a research note on Thursday, August 13th. Bank of America reaffirmed a "buy" rating on shares of AbbVie in a research note on Tuesday, September 8th. Canaccord Genuity Group boosted their price target on AbbVie from $282.00 to $290.00 and gave the company a "buy" rating in a report on Monday, August 3rd. Finally, Erste Group Bank raised AbbVie from a "hold" rating to a "buy" rating in a research note on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $277.18.

AbbVie Price Performance

Shares of NYSE:ABBV traded down $4.03 on Tuesday, hitting $277.10. 977,350 shares of the company's stock were exchanged, compared to its average volume of 6,386,264. AbbVie has a 12 month low of $190.75 and a 12 month high of $283.43. The stock has a market capitalization of $489.57 billion, a price-to-earnings ratio of 78.30, a price-to-earnings-growth ratio of 1.26 and a beta of 0.24. The business's 50 day simple moving average is $259.79 and its two-hundred day simple moving average is $237.39.

AbbVie (NYSE:ABBV - Get Free Report) last issued its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business's revenue was up 10.2% on a year-over-year basis. During the same period in the previous year, the firm earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities analysts forecast that AbbVie will post 13.94 EPS for the current fiscal year.

Insider Activity

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.06% of the company's stock.

Institutional Trading of AbbVie

Hedge funds have recently bought and sold shares of the stock. Corient Private Wealth LP bought a new position in shares of AbbVie during the 2nd quarter worth approximately $559,736,000. Legal & General Group Plc purchased a new stake in AbbVie during the second quarter valued at approximately $2,905,952,000. Jupiter Topco LLC purchased a new stake in AbbVie during the second quarter valued at approximately $1,560,354,000. Diamant Asset Management Inc. boosted its stake in AbbVie by 21,649.0% in the first quarter. Diamant Asset Management Inc. now owns 3,671,231 shares of the company's stock valued at $798,456,000 after acquiring an additional 3,654,351 shares in the last quarter. Finally, Canada Pension Plan Investment Board acquired a new stake in AbbVie in the second quarter valued at approximately $817,473,000. Hedge funds and other institutional investors own 70.23% of the company's stock.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Royal Bank of Canada reaffirmed its Outperform rating and set a $280 price target, indicating continued confidence in AbbVie’s outlook, although the target implies only modest near-term upside. TickerReport article
• Positive Sentiment: Skyrizi and Rinvoq are expected to be the primary drivers of third-quarter revenue growth, helping offset the continued decline of Humira. Long-term data presented at ACG 2026 also support the durability of these products. Yahoo Finance article
• Positive Sentiment: Investors remain focused on AbbVie’s pipeline expansion, including a recently completed acquisition and a new FDA approval that could create another billion-dollar growth opportunity. 247WallSt article
• Neutral Sentiment: AbbVie was highlighted in broader discussions of pharmaceutical merger activity, as large drugmakers pursue acquisitions to address upcoming patent cliffs. This supports sector interest but does not provide a company-specific catalyst by itself. ETF Trends article
• Negative Sentiment: Humira’s ongoing erosion and increasing competition in immunology remain key risks. In addition, AbbVie’s elevated valuation and the limited upside to RBC’s target may encourage investors to lock in gains after the stock’s recent rally. Motley Fool article

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women's health.

The company's products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.